MedTrace Logo

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

NCT00335933 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 378

Last updated 2007-08-02

No results posted yet for this study

Summary

Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control. The purpose of this study is to determine whether a new gabapentin tablet, which only needs to be taken once or twice a day, is safe and effective for the treatment of postherpetic neuralgia.

Conditions

  • Neuralgia, Postherpetic

Interventions

DRUG

Gabapentin extended-release tablets

Sponsors & Collaborators

  • Depomed

    lead INDUSTRY

Principal Investigators

  • Bret Berner, Ph.D. · Sponsor/Depomed, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00335933 on ClinicalTrials.gov